Nasdaq

Biocept Announces CE-IVD Mark and Availability of its Target Selector™ EGFR Molecular Assay Kit in Europe

Target Selector™ assay kits enable assay developers to leverage Biocept's patented, high-sensitivity technology for the detection of key actional oncogene mutations from both tissue biopsies and blood ...
Business Wire

Medicare Issues Local Coverage Determination for Biocept’s Target Selector™ Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells

“Target Selector is a highly sensitive assay for identifying HER2 status that is less invasive, more time-efficient and more cost-effective than tissue biopsy,” said Michael Dugan, M.D., Biocept’s ...
Nasdaq

Data Affirming Biocept's Target Selector™ Platform Identifies Cancer Mutations in Cerebrospinal Fluid Presented at ASCO 2020 Virtual Scientific Program

Target Selector™ platform shown to be potentially more sensitive than standard-of-care cytology in detecting mutations of brain metastases in cerebrospinal fluid SAN DIEGO, May 29, 2020 /PRNewswire/ - ...
Business Wire

Study Shows Biocept’s Target Selector™ Detects Mutations in “Quantity Not Sufficient” Specimens in Non-Small Cell Lung Cancer Patients

SAN DIEGO--(BUSINESS WIRE)--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will present data showing that its Target Selector™ molecular assay ...
Proactiveinvestors

Biocept expands molecular assay offering with release of Target Selector BRAF kit

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return ...